Boehringer’s Striverdi Respimat inhalation spray gets FDA approval for COPD treatment
Striverdi Respimat, a long-acting beta agonist (LABA) delivered via a propellant-free inhaler, is not indicated for the treatment of acute deteriorations of COPD and also for asthma. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.